Clinical Scorecard: Development of chronic inflammatory demyelinating polyneuropathy (CIDP) following cilta-cel treatment
At a Glance
Category
Detail
Condition
Chronic inflammatory demyelinating polyneuropathy (CIDP) as a rare immune-mediated neurological complication
Key Mechanisms
T-cell and antibody-driven inflammation and demyelination of peripheral nerves; involvement of BCMA-specific CAR-T cells detected in blood and CSF
Target Population
Patients with relapsed/refractory multiple myeloma treated with BCMA-targeting CAR-T cell therapy (cilta-cel)
Care Setting
Specialized oncology and neurology care settings with capacity for CAR-T therapy and management of neurological complications
Key Highlights
CIDP can develop as a delayed neurological complication following BCMA-specific CAR-T cell therapy (cilta-cel) in multiple myeloma patients.
Neurological symptoms include progressive motor and sensory deficits, gait ataxia, cranial nerve palsies, and mixed sensorimotor axonal demyelinating polyneuropathy confirmed by electrophysiology.
Treatment with high-dose dexamethasone, intravenous immunoglobulin, and cyclophosphamide showed partial to marked neurological improvement in some patients, though serious infectious complications may occur.
Guideline-Based Recommendations
Diagnosis
Perform electromyography and nerve conduction studies to identify sensorimotor axonal demyelinating polyneuropathy.
Exclude infectious causes with blood tests and CSF analysis including viral panels and malignant cell assessment.
Use imaging (cranial MRI, CT) and EEG to rule out other neurological abnormalities.
Management
Initiate high-dose dexamethasone and intravenous immunoglobulin as standard CIDP treatment.
Consider cyclophosphamide administration to deplete T-cell activity in progressive or refractory cases.
Use intrathecal chemotherapy or dexamethasone for CSF inflammatory control when indicated.
Monitoring & Follow-up
Monitor CAR-T cell levels in peripheral blood and CSF to correlate with neurological status and treatment response.
Track inflammatory markers such as C-reactive protein and ferritin.
Regularly assess neurological function and perform serial electrophysiological studies.
Risks
Be vigilant for serious infectious complications including pneumonia, invasive aspergillosis, COVID-19 pneumonia, and urosepsis due to immunosuppression.
Recognize potential for progressive neurological deterioration despite treatment.
Monitor for additional neurological events such as infarctions.
Patient & Prescribing Data
Two female patients aged 65 and 73 years with relapsed multiple myeloma and extramedullary lesions treated with cilta-cel
Early toxicities were limited; CIDP symptoms developed between day 19 and day 112 post-infusion; immunosuppressive therapies led to partial or marked neurological improvement in one patient and fatal progression in the other.
Clinical Best Practices
Early recognition of delayed neurological symptoms post-CAR-T therapy is critical for timely diagnosis and intervention.
Comprehensive diagnostic workup including electrophysiology, imaging, CSF analysis, and infectious screening is essential.
Multimodal immunosuppressive treatment combining corticosteroids, IVIG, and cyclophosphamide may improve outcomes.
Close monitoring for infectious complications and supportive care in intensive care settings may be necessary.
Tracking CAR-T cell kinetics and T-cell subset dynamics can inform treatment response and disease progression.
by M. Korenkov, J. Liebaert, S. Yousefian, S. Schwartz, U. M. Demel, J. Braune, M. C. Odabasi, L. Herzberg, D. Böckle, N. C. Görür, V. v. Landenberg-Roberg, S. Bohl, E. Tregel, S. Hennig, C. Franke, S. Haas, U. Keller, J. Krönke, A. Busse
